Loss of heterozygosity of hereditary pancreatic cancer susceptibility genes such as BRCA1/2 plays a key role in carcinogenesis and sensitivity to PARP inhibitors. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.